Form 4: Altimmune Director Klaus Schafer Reports Stock Option Grant

Director Klaus Schafer reports the acquisition of stock options in Altimmune, Inc.

Summary

• Klaus Schafer, a director of Altimmune, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Schafer on September 26, 2024.
• The options allow Schafer to purchase 34,900 shares of Altimmune common stock at an exercise price of $6.81 per share.
• The options vest in equal monthly installments over 12 months, contingent on continued service.
• Schafer also granted power of attorney to Vipin K. Garg and Andrew Shutterly to handle SEC filings.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is also typical.
• Comparable companies in the biotech industry, such as Madrigal Pharmaceuticals and Viking Therapeutics, also utilize stock options as part of their executive compensation plans.

Key Dates